Nvidia's Favorite Drug Company Wants to Go Public

Iambic's platform, called Enchant, is trying to change the order of operations. It's a multimodal AI model trained on dozens of data sources: lab results, protein structures, clinical trial data, and more. Instead of optimizing one property at a time ("Does this molecule bind well?"), Enchant tries to predict many properties at once: how the drug moves through the body, whether it's toxic, how it might perform in humans.

The AI doesn't work alone. It's paired with NeuralPLexer, a structure-prediction tool, and plugged into automated chemistry and biology labs. The whole system runs in a loop: the AI designs molecules, the robots make and test them, and the results feed back into the model. Think of it as a self-improving drug factory where every experiment makes the next one smarter.

Co-founder and CEO Thomas Miller and co-founder and CTO Fred Manby built the platform around this closed-loop concept. The pitch is that it compresses timelines and improves success rates by testing many hypotheses in parallel rather than one at a time.

What's Actually in the Pipeline

Platform stories are great, but investors want drugs. Iambic has three programs, and only one is in the clinic.

The lead candidate, IAM1363, targets HER2-altered cancers and is currently in a Phase 1/1b trial. HER2 is a well-known cancer target (think Herceptin), so Iambic isn't swinging at an obscure biology. It's trying to prove its AI can build a better drug against a known problem.

Behind that sit IAM217 (targeting a protein called KIF18A) and IAM-C1 (targeting CDK2/4). Both are still in preclinical work, with IND filings expected in Q4 2026. That means they're at least a year away from generating human data.

This is important context. Iambic is still very early-stage. The IPO proceeds will fund continued development, not commercialization. Investors are buying the platform thesis and the promise of clinical data, not revenue.

The AI Biotech IPO Wave Is Real

Iambic isn't filing into a vacuum. The IPO window for AI drug discovery companies has been wide open in 2026.

Generate:Biomedicines priced a $400 million IPO in February, one of the largest biotech listings of the year. Eikon Therapeutics raised $381 million in the same month. In the first half of 2026, AI and machine learning biotech IPOs raised about $2.1 billion across seven deals, with the pace accelerating in Q2 (five IPOs, $1.6 billion) compared to Q1 (two IPOs, $501 million).

Broader biotech IPO performance has been strong, too. One dataset showed 55% weighted-average returns for U.S. biotech and pharma IPOs through mid-July. As Matt Kennedy of Renaissance Capital noted, the year's best-performing IPOs have all been biotechs, "much of that being driven by drug advancement and M&A."

That rising tide is real, but it's not lifting all boats equally. The market is rewarding companies with clinical data, big pharma partnerships, or clearly differentiated technology. Pure-platform plays without clinical proof are facing tougher questions.

The $100 Million Question

Iambic checks several boxes that investors care about right now: a credible AI platform, blue-chip backers, and a lead program in human trials. The HER2 program gives it a concrete narrative beyond "we have cool technology." And the investor syndicate (Nvidia! Qatar! Sequoia! Regeneron!) provides social proof that sophisticated money has already validated the story.

But there are real risks. One drug in Phase 1. Two more that haven't reached the clinic. No revenue. No partnerships with major pharma that have been disclosed in the filing materials. The company is asking public investors to fund what is essentially a very expensive science experiment.

The next milestone to watch is the amended S-1, which will reveal the actual price range and deal size. That's when we'll learn how Wall Street is really valuing the AI-meets-cancer-drugs narrative.

For now, Iambic's filing is the clearest signal yet that AI drug discovery has graduated from venture capital darling to public market contender. Whether public investors are as enthusiastic as Nvidia remains to be seen. But if the 2026 IPO window is any guide, the appetite is there; the question is the price.

Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.